* Images for illustrative purposes only
* Brand supplied may vary depending on stock availability
Same-day service available for additional £10, conditions apply.
No appointment or long waiting times
Your information always remains private
All our doctors & pharmacists are qualified & based in the UK
Dispensed by our UK partner pharmacies
Choose from our treatment options or speak to the in-store pharmacist for advice
Complete our free online medical consultation to be reviewed by our Clinical Team
We will notify you when your medication is ready for collection
Evorel Sequi patches are a form of hormone replacement therapy (HRT) specifically designed for women experiencing menopausal symptoms, particularly those who have not undergone a hysterectomy and require sequential hormone therapy. Each patch contains a combination of estradiol and norethisterone, with the estradiol component addressing menopausal symptoms, while norethisterone, a progestogen, helps protect the endometrium from hyperplasia that can occur with estrogen therapy.
Evorel Sequi patches are utilized in a specific regimen: the estradiol-only patches are worn for the first two weeks, followed by a combination patch containing both estradiol and norethisterone for the subsequent two weeks. This sequential approach mimics the natural menstrual cycle, allowing for the regulated administration of hormones.
Clinical studies have demonstrated that Evorel Sequi patches effectively reduce the frequency and severity of menopausal symptoms, such as hot flashes, night sweats, and vaginal dryness. Many users report significant improvements in their quality of life, as the patches alleviate bothersome symptoms that can negatively impact daily activities and overall well-being.
The efficacy of Evorel Sequi is supported by evidence indicating that it offers substantial relief from menopausal symptoms while also providing protection against endometrial hyperplasia, thereby reducing the risk of uterine-related complications. Users of Evorel Sequi experience not only a decrease in vasomotor symptoms but also improvements in mood and sleep quality, enhancing overall quality of life.
While generally well tolerated, Evorel Sequi patches can be associated with side effects such as skin reactions at the application site, headaches, breast tenderness, and mood changes. Serious but rare complications may include an increased risk of thromboembolic events, such as deep vein thrombosis or pulmonary embolism. Therefore, it is important for patients to discuss their individual risk factors and medical history with their healthcare provider prior to starting treatment.
Evorel Sequi patches are contraindicated in women with certain conditions, including a history of hormone-sensitive cancers, severe liver disease, or a history of blood clots. Thorough evaluation by a healthcare provider is necessary to determine the appropriateness of the therapy.
In summary, Evorel Sequi patches provide an effective and tailored method for managing menopausal symptoms through a sequential hormone therapy approach. Their ability to deliver relief from symptoms, along with protections against endometrial changes, makes them a valuable option for many women during menopause. Regular follow-ups with healthcare providers are essential to monitor treatment efficacy and manage any side effects.
Evorel Sequi patches are designed for hormone replacement therapy (HRT) to treat menopausal symptoms in women. Each pack includes two different types of patches: the estradiol-only patches and the combined estradiol and norethisterone patches. The typical regimen involves applying one estradiol-only patch for the first 14 days, followed by one combined patch for the next 14 days, creating a 28-day cycle.
To use Evorel Sequi, the patch should be applied to a clean, dry, and hairless area of skin, such as the abdomen, buttocks, or upper arm. It is important to press the patch firmly onto the skin for about 30 seconds to ensure proper adhesion. The patches should be changed twice a week, typically every 3 to 4 days, and the application site should be rotated to minimize skin irritation.
If you miss applying an Evorel Sequi patch and realize it within a few hours, apply it as soon as you remember. If it has almost been time to apply the next patch, skip the missed patch and continue with your regular schedule without applying an additional patch to make up for the missed dose.
For optimal effectiveness, it is recommended to apply the patches at the same time each day, and regular follow-up appointments with your healthcare provider are essential to monitor the relief of symptoms and any potential side effects. If you have any questions about how to use Evorel Sequi patches or concerns regarding missed doses, consult your healthcare provider for further guidance.
Always use this medication exactly as your clinician has told you. Check with our clinical team or your GP or pharmacist if you are not sure.
Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect.
Evorel Sequi is a transdermal patch that delivers a combination of estradiol (an estrogen) and levonorgestrel (a progestogen) for hormone replacement therapy (HRT). It is designed for women who still have their uterus and need both estrogen and progestogen to relieve menopausal symptoms while minimizing the risk of endometrial hyperplasia. Here are the detailed side effects associated with Evorel Sequi:
1. Skin Reactions Irritation, redness, or rash at the application site.
2. Breast Changes Tenderness, swelling, or changes in breast tissue.
3. Headaches Including migraines or tension-type headaches.
4. Nausea Gastrointestinal upset may occur.
5. Weight Changes Some women may experience weight gain or loss.
1. Mood Changes Anxiety, depression, or mood swings.
2. Gastrointestinal Issues Diarrhea or stomach cramps.
3. Fluid Retention Swelling in the ankles or hands.
1. Thromboembolic Events Increased risk of blood clots, deep vein thrombosis, pulmonary embolism, and stroke.
2. Cardiovascular Issues Potential increase in blood pressure or heart attack risk.
3. Endometrial Hyperplasia Overgrowth of the uterine lining, which can lead to abnormal bleeding.
4. Liver Problems Changes in liver function or liver disease.
For full information on side effects and correct use, see the patient information leaflet. If any side effects concern you, or you are experiencing any of the side effects mentioned in the patient information leaflet whilst taking this medication, please contact our clinical team or speak to your GP.
Evorel Sequi patches are a form of hormone replacement therapy (HRT) that deliver estradiol and norethisterone in a sequential regimen to help manage menopausal symptoms in women who still have their uterus. Here are the detailed cautions and warnings associated with Evorel Sequi patches:
1. Dosage and Administration: Adhere strictly to the prescribed regimen. Overuse or incorrect application of the patches can lead to elevated estradiol levels, resulting in potential side effects and complications.
2. Cardiovascular Risks: Evorel Sequi patches can increase the risk of thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE). Women with a history of cardiovascular disease, smoking, obesity, or prolonged immobility are at higher risk.
3. Breast Cancer Risk: Prolonged use of estrogen therapy, especially in combination with progestogen, may be associated with an increased risk of breast cancer. Regular breast examinations and mammograms are crucial for early detection.
4. Endometrial Cancer: For women who still have a uterus, unopposed estrogen therapy can promote endometrial hyperplasia and increase the risk of endometrial cancer. A progestogen is usually prescribed alongside estrogen for these patients.
5. Liver Conditions: Women with liver disease should use Evorel Sequi patches with caution as they are metabolized in the liver. Liver function tests should be monitored periodically.
6. Hormone-Sensitive Conditions: Patients with a history of hormone-sensitive conditions (such as certain cancers, endometriosis, or uterine fibroids) should consult their healthcare provider before using Evorel Sequi.
7. Hypertension: Estrogen can affect blood pressure. Regular monitoring of blood pressure is recommended, especially for individuals with a history of hypertension.
8. Drug Interactions: Evorel Sequi may interact with certain medications, including those that induce liver enzymes (such as certain anticonvulsants and antimycotics). Inform your healthcare provider about all medications and supplements you are taking.
9. Psychological Effects: Hormonal therapy can influence mood and mental health. Patients should report any significant mood changes, depression, or unusual emotional symptoms to their healthcare provider.
10. Pregnancy and Breastfeeding: Evorel Sequi patches should not be used during pregnancy or while breastfeeding due to potential risks to the fetus or infant.
11. Cholesterol Levels: Hormonal therapy can affect lipid profiles. Regular monitoring of lipid levels may be necessary, especially in women with a history of dyslipidemia.
12. Age Considerations: The risk of thromboembolic events may increase with age, particularly for women over 60. Use should be carefully considered in this population.
Get emergency medical help if you have signs of an allergic reaction to this medication. These include:
It is important that you let us know which prescription, over-the-counter medicines and recreational drugs you are currently taking. You must also tell us about any other medical conditions that you currently have (or had in the past). This will help us ensure the prescribed medication is safe and appropriate for you to take.
For full information on warnings, medication interactions and contraindications, refer to the Patient Information Leaflet. Please read all packaging and the Patient Information Leaflet before taking any new medicine and inform our clinical team or your GP of medicines you are taking or intend to take.
